709 filings
Page 2 of 36
S-8 POS
ie3c9lryp0mgb7e3qub
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:51pm
S-8 POS
8wo73o3u
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:51pm
S-8 POS
lhjv87
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:50pm
S-8 POS
n8ou 0doa49
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:50pm
S-8 POS
t56icufkvu6pdzv
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:49pm
S-8 POS
v1kc2q4ylf
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:49pm
25-NSE
aqvwbw
25 Jan 23
Exchange delisting
9:23am
8-K
twgt4oo8t
18 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:32am
8-K
i25ak6c95k mw
17 Jan 23
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
6:20am
8-K
nbl82gk ke0nhwcr6
15 Dec 22
Viveve Announces Completion of Pivotal U.S. PURSUIT Trial
8:29am
8-K
0f1o0
2 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:12pm
8-K
d6rg2mxmyw4eu
1 Dec 22
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
8:29am
8-K
r5vc6v2nrosart8
23 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
5mpglhxfymhp
10 Nov 22
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:03pm
D
q9t27on35ddn
26 Oct 22
$14.68 k in equity, sold $14.68 k, 1 investor
6:58pm
8-K
47x0quv eweb5i5
4 Oct 22
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
8:29am
EFFECT
ow3fe1ur7n2yrkk1g
29 Sep 22
Notice of effectiveness
12:15am